Vertex Pharmaceuticals | VRTX

Stock Price
445.87
Daily Change
0.46 0.10%
Monthly
11.63%
Yearly
31.15%
Q2 Forecast
433.25
Peers Price Chg Day Year Date
AbbVie 164.49 -1.71 -1.03% 13.52% May/20
Acadia Pharmaceuticals 15.10 0.31 2.10% -39.11% May/20
Agios Pharmaceuticals 33.19 -1.15 -3.35% 24.35% May/20
Alnylam Pharmaceuticals 150.24 0.84 0.56% -22.18% May/20
Amgen 314.25 1.89 0.60% 40.14% May/20
Arrowhead Research 24.82 0.05 0.20% -32.04% May/20
Biogen 231.65 1.11 0.48% -24.16% May/20
BioMarin Pharmaceutical 77.05 -0.51 -0.66% -16.95% May/20
Bristol-Myers Squibb 43.31 -0.71 -1.61% -34.19% May/20
Gilead Sciences 67.86 0.17 0.25% -13.69% May/20
Incyte 57.21 0.10 0.18% -10.09% May/20
Insmed 25.54 0.77 3.11% 25.75% May/20
Ionis Pharmaceuticals 38.72 1.41 3.78% -4.89% May/20
J&J 151.29 -3.30 -2.13% -4.54% May/20
Merck 130.99 -0.06 -0.05% 14.90% May/20
Moderna 141.02 8.20 6.17% 11.27% May/20
Neurocrine Biosciences 141.65 -0.64 -0.45% 51.50% May/20
Novartis 93.76 0.39 0.42% 2.76% May/21
Pfizer 28.49 -0.10 -0.35% -26.48% May/20
PTC Therapeutics 40.12 7.02 21.21% -32.12% May/20
Ultragenyx Pharmaceutical 41.53 -0.34 -0.81% -18.10% May/20
Regeneron Pharmaceuticals 986.04 17.55 1.81% 31.92% May/20
Roche Holding 236.05 -1.05 -0.44% -17.58% May/21
Sanofi 88.89 -0.27 -0.30% -11.38% May/21
Sarepta Therapeutics 130.83 -0.55 -0.42% -12.24% May/20
United Therapeutics 274.67 0.41 0.15% 25.66% May/20
Vertex Pharmaceuticals 445.87 0.46 0.10% 31.15% May/20

Indexes Price Day Year Date
US500 5311 4.86 0.09% 26.67% May/21
USND 16795 108.91 0.65% 32.03% May/20
US400 3020 3.40 0.11% 22.32% May/20
US100 18678 127.96 0.69% 34.86% May/21

Vertex Pharmaceuticals traded at $445.87 this Monday May 20th, increasing $0.46 or 0.10 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals gained 11.63 percent. Over the last 12 months, its price rose by 31.15 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 433.25 by the end of this quarter and at 420.76 in one year, according to Trading Economics global macro models projections and analysts expectations.

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.